<DOC>
	<DOCNO>NCT01612039</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-blind , multicenter , parallel , placebo control study . Approximately 120 eligible patient mild-to-moderate active ulcerative colitis randomize double blind treatment either 1,000 mg twice daily ( b.i.d . ) ASP3291 ( 2,000 mg/d ) match placebo 1:1 ratio 8 week . The study hypothesis treatment ASP3291 compare placebo improve patient 's ulcerative colitis endoscopic score baseline Week 8 .</brief_summary>
	<brief_title>Safety , Efficacy , Tolerability Study ASP3291 Patients With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Documented diagnosis ulcerative colitis endoscopy histology consistent diagnosis Must able provide inform consent Has Modified Baron Score least 2 ( determine investigator ) 15 cm anal verge assess screening period Has Ulcerative Colitis Clinical Score ( UCCS ) least 4 , stool frequency rectal bleed score least 1 assessed screening period If female , least 2 year postmenopausal , surgically sterile per documentation provide medical professional , agree sexual abstinence , use two approve highly effective method birth control study period 30 day last dose study drug If male , agree sexual abstinence use two highly effective method birth control study period 90 day last dose ; agree donate sperm study period 90 day last dose Willing able comply study requirement Has history clinically significant neurological , renal , hepatic , gastrointestinal , pulmonary , metabolic , cardiovascular , psychiatric , endocrine , hematological disorder disease , medical condition , investigator 's opinion , would preclude participation study Has severe Ulcerative Colitis define average bloody stool frequency &gt; 6 per day least one following : Resting heart rate &gt; 90 bpm Oral temperature &gt; 38°C ( &gt; 100.4°F ) Hemoglobin &lt; 10.5 g/dL Has undergone previous resective colonic surgery Has significant immediate risk toxic megacolon Has previous diagnosis Crohn 's disease , indeterminate colitis , microscopic colitis acute diverticulitis base medical history Has extension disease limit ulcerative proctitis ( i.e. , disease extension less 15 cm anal verge ) Has active peptic ulcer disease base medical history Shows stool culture positive enteric pathogen screen period Had previous treatment tumor necrosis factorα ( TNF α ) inhibitor Had treatment rectal corticosteroid within 2 week Day 2 Has active liver disease alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal ( ULN ) screening Has estimate glomerular filtration rate ( use CockroftGault formula correct body surface area ) &lt; 60 mL/min screen Known history human immunodeficiency virus antibody History severe allergic anaphylactic reaction require medical attention Has participate another investigational study within 30 day Visit 3 History drug alcohol abuse past 2 year Has previously participate study ASP3291</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ulcerative colitis</keyword>
</DOC>